COVID-19 Staff Shakeup: Woodcock Moves to Commissioner's Office As Marks Drops Out Of 'Warp'

 
• By Sarah Karlin-Smith

CBER Director Marks will no longer have to recuse himself from COVID-19 product reviews, a move seen as resoundingly positive by former senior FDA leaders. CDER Director Woodcock will now be free to focus solely on COVID-19 and bring her unique depth of agency experience to the Trump Administration's effort to speed development of vaccines, therapeutics and diagnostics for coronavirus.

Restructuring the company to better face the present reality
Key staffing changes are being made at FDA to tackle COVID-19 • Source: Shutterstock

More from US FDA

More from Agency Leadership